drugset / Trial / NCT04771780
Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
NaSingle-groupOpen-labelTreatment
Summary
To investigate the safety of repeated administration of KHK7791 for 52 weeks while switching from a phosphate-binding agent to KHK7791 in Hemodialysis patients with hyperphosphatemia.
Timeline
- Start
- 2021-03-15
- Primary completion
- 2022-06-27
- Completion
- 2022-06-27
Publications
- Nagano N, Tokunaga S, Asada S, Fukagawa M, Akizawa T. Tenapanor reduces phosphate binder pill burden among hemodialysis patients in a post hoc phase 3 analysis. Sci Rep. 2026 Jul 1. doi: 10.1038/s41598-026-58594-9. Online ahead of print.
- Koiwa F, Sato Y, Ohara M, Nakanishi K, Fukagawa M, Akizawa T. Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia. Sci Rep. 2023 Nov 4;13(1):19100. doi: 10.1038/s41598-023-45080-9.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tenapanor | Small molecule | 5 mg | Oral |
| Subject | Tenapanor | Small molecule | 30 mg | Oral |